Skip to Main Content

Paper Details

Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function.
Breast Cancer Research and Treatment
15
2021
HER2, HER2-positive breast cancer, anthracyclines, breast cancer, cancer, cardiac, cardiac deaths, cardiac dysfunction, cardiotoxicity, compromised heart, compromised heart function, heart failure, patient, patients, pertuzumab, trastuzumab
Author NameAffiliation
Claudine IsaacsLombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital
Claudine IsaacsGeorgetown University
  • 1 - 2

Datasets

Release 1.2